Geode Capital Management LLC Sells 377,048 Shares of Dynavax Technologies Corporation $DVAX

Geode Capital Management LLC lowered its holdings in Dynavax Technologies Corporation (NASDAQ:DVAX) by 12.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,688,774 shares of the biopharmaceutical company’s stock after selling 377,048 shares during the quarter. Geode Capital Management LLC owned approximately 2.24% of Dynavax Technologies worth $26,676,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the stock. Vise Technologies Inc. bought a new stake in shares of Dynavax Technologies in the 2nd quarter valued at about $231,000. Los Angeles Capital Management LLC acquired a new position in Dynavax Technologies during the 2nd quarter valued at approximately $321,000. Fox Run Management L.L.C. acquired a new position in shares of Dynavax Technologies in the 2nd quarter valued at $200,000. Corton Capital Inc. acquired a new position in shares of Dynavax Technologies in the second quarter valued at about $226,000. Finally, Bank of Montreal Can boosted its position in Dynavax Technologies by 5.4% in the second quarter. Bank of Montreal Can now owns 249,203 shares of the biopharmaceutical company’s stock valued at $2,472,000 after buying an additional 12,732 shares during the last quarter. 96.96% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. JMP Securities reissued a “market outperform” rating and issued a $32.00 price objective on shares of Dynavax Technologies in a report on Friday, August 22nd. Wall Street Zen raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Dynavax Technologies has a consensus rating of “Hold” and a consensus price target of $24.33.

Dynavax Technologies Trading Down 0.5%

Shares of DVAX opened at $11.37 on Friday. The stock has a market cap of $1.34 billion, a PE ratio of -24.72 and a beta of 1.09. Dynavax Technologies Corporation has a 52-week low of $9.20 and a 52-week high of $14.63. The firm’s fifty day moving average is $10.45 and its two-hundred day moving average is $10.34. The company has a quick ratio of 6.01, a current ratio of 6.65 and a debt-to-equity ratio of 0.45.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.07. The business had revenue of $94.88 million for the quarter, compared to analysts’ expectations of $94.00 million. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%. Research analysts forecast that Dynavax Technologies Corporation will post 0.32 earnings per share for the current fiscal year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.